RAD21 alterations are relatively common according to TCGA PanCancer atlas studies (7% of all queried patients), which show elevated RAD21 in 20% of ovarian cancer cases and 13% of breast cancer cases. This evidence concerns the gene RAD21 and ovarian carcinoma.